Can I Take Folate with MK-677 (Ibutamoren)?

What MK-677 Actually Does in the Body

MK-677 (ibutamoren mesylate) is an orally active, non-peptide ghrelin-receptor agonist that stimulates pulsatile growth hormone (GH) release from the pituitary without suppressing the hypothalamic-pituitary axis. Downstream, it raises circulating IGF-1 within days of starting treatment. A 2-year randomized controlled trial in 65 healthy older adults (mean age 69) showed that 25 mg/day of MK-677 raised serum IGF-1 by roughly 60% over placebo and increased fat-free mass by 1.5 kg without significant changes in fat mass at 12 months 1.

Receptor Mechanism

MK-677 binds the growth hormone secretagogue receptor 1a (GHSR-1a), the same receptor activated by the hunger hormone ghrelin. Binding triggers a Gq-protein cascade that increases intracellular calcium in pituitary somatotrophs, releasing stored GH in a pulsatile pattern that mimics physiologic secretion 2.

IGF-1 Elevation and Its Downstream Effects

The spike in IGF-1 produced by MK-677 is the primary driver of its anabolic effects, including lean-mass accretion and improved nitrogen retention. A Phase II trial by Murphy et al. (N=24 hip-fracture patients) found that 25 mg/day for 6 weeks raised IGF-1 by 84% and improved functional outcomes on a rehabilitation scale compared to placebo 3. IGF-1 also interacts indirectly with one-carbon metabolism, a relationship covered in the folate section below.

What MK-677 Does Not Do

MK-677 does not inhibit cytochrome P450 enzymes at research doses, does not bind folate transporters, and has no documented effect on methylenetetrahydrofolate reductase (MTHFR) activity. That point matters because it narrows the interaction question to pharmacodynamic territory rather than pharmacokinetic.

How Folate Works: A Brief Mechanistic Primer

Folate (vitamin B9) is a water-soluble B-vitamin required for the synthesis of purines, thymidylate, and methionine from homocysteine. Dietary folate and folic acid (the synthetic, oxidized form) must be reduced by dihydrofolate reductase (DHFR) and then converted by MTHFR to 5-methyltetrahydrofolate (5-MTHF), the biologically active form that donates a methyl group to remethylate homocysteine 4.

The MTHFR Variant Problem

About 10 to 15% of individuals of European ancestry carry the homozygous MTHFR C677T variant (TT genotype), which reduces MTHFR enzyme activity by up to 70% 5. Carriers accumulate 5,10-methyleneTHF and produce less 5-MTHF, raising plasma homocysteine. The heterozygous CT genotype, present in roughly 40 to 50% of some populations, reduces activity by about 35% 5.

L-Methylfolate vs. Folic Acid

Supplementing with L-methylfolate (5-MTHF) bypasses the MTHFR conversion step entirely. A comparative pharmacokinetic study showed that oral L-methylfolate 400 mcg raised plasma 5-MTHF area-under-curve 1.7-fold compared with the same dose of folic acid in healthy adults 6. For anyone on MK-677 who also has a confirmed MTHFR variant, L-methylfolate is the preferred supplemental form.

Folate Deficiency: Who Is at Risk

Groups with elevated deficiency risk include those following restrictive diets, anyone taking methotrexate or trimethoprim (which inhibit DHFR), pregnant women, heavy alcohol users, and individuals with malabsorptive conditions such as celiac disease 7. MK-677 itself does not belong to any of these categories.

Is There a Direct Pharmacokinetic Interaction?

No. MK-677 is metabolized primarily by cytochrome P450 3A4 (CYP3A4) and does not meaningfully inhibit or induce CYP1A2, CYP2C9, CYP2D6, or CYP3A4 at the 25 mg clinical dose 8. Folate and its reduced forms are transported via the reduced folate carrier (RFC-1, SLC19A1) and the proton-coupled folate transporter (PCFT, SLC46A1). Neither transporter is affected by GHSR-1a agonism.

Absorption Pathways Do Not Overlap

MK-677 is absorbed in the proximal small intestine through passive transcellular diffusion. Folate is absorbed predominantly in the proximal jejunum through PCFT-mediated active transport at low pH and via RFC-1 at physiologic pH 9. There is no competition for the same transporter, no pH-dependency conflict, and no reported alteration of folate bioavailability in the presence of ghrelin-receptor agonists.

Protein Binding and Distribution

MK-677 is approximately 97% protein-bound in plasma, primarily to albumin. Folate circulates partly as free 5-MTHF and partly bound to folate-binding proteins (FBP). No displacement interaction between these two has been documented in in vitro binding studies or clinical pharmacokinetic literature.

The Indirect Link: IGF-1, Homocysteine, and Methylation

This is where the clinical rationale for monitoring folate status actually lives. Elevated IGF-1 concentrations may modestly increase homocysteine through two mechanisms: increased cellular proliferation raises demand for methyl donors, and IGF-1 signaling through PI3K/Akt may downregulate cystathionine beta-synthase (CBS) activity, slowing the transsulfuration pathway that clears homocysteine 10.

What the Evidence Says About IGF-1 and Homocysteine

A cross-sectional analysis of 1,754 adults in the Framingham Offspring Study found an inverse relationship between IGF-1 and homocysteine after adjustment for age, sex, and renal function (P<0.05), suggesting that acute pharmacologic IGF-1 elevation might transiently perturb homocysteine balance in a subset of users 10. The effect size was modest, and causality was not established in that observational dataset.

Why This Matters for MK-677 Users

If MK-677 raises IGF-1 by 60 to 84% (as documented in clinical trials), and if that elevation exerts even a fraction of the homocysteine-raising tendency seen at high-physiologic IGF-1 concentrations, users with borderline folate status or an MTHFR variant may develop mildly elevated homocysteine over weeks to months. This is not a certainty but a plausible pharmacodynamic consideration that justifies baseline homocysteine testing before starting MK-677 and a recheck at 8 weeks.

The HealthRX Folate-Plus-MK-677 Decision Framework

The following decision logic is based on the mechanistic evidence above and standard clinical practice for managing homocysteine risk:

1. Test baseline: total homocysteine, serum folate, RBC folate, serum B12, and complete metabolic panel (for renal function, since kidney disease independently raises homocysteine).
2. If homocysteine is below 10 micromol/L and no MTHFR variant is known: standard dietary folate (400 mcg/day from food or a multivitamin containing folic acid) is adequate. No special folate supplementation is required before starting MK-677.
3. If homocysteine is 10 to 15 micromol/L or MTHFR CT/TT genotype is confirmed: start L-methylfolate 400 to 1,000 mcg/day before or concurrent with MK-677. Add methylcobalamin (B12) 500 to 1,000 mcg/day because B12 is the cofactor for methionine synthase.
4. If homocysteine exceeds 15 micromol/L: do not start MK-677 until the elevation is evaluated and managed. Elevated homocysteine at this level is an independent cardiovascular risk factor per the American Heart Association 11.
5. Recheck homocysteine and IGF-1 at 8 weeks on MK-677. Adjust folate dose based on results.

Folate Safety Profile and Tolerable Upper Limits

Folate is water-soluble. Excess is renally cleared, and toxicity from food folate has not been reported in humans 7. The tolerable upper intake level (UL) for folic acid (synthetic form) from fortified foods and supplements is 1,000 mcg/day for adults, set primarily to avoid masking vitamin B12 deficiency rather than direct toxicity 7.

High-Dose Folate Cautions

Doses above 1,000 mcg/day of folic acid may mask the hematologic signs of pernicious anemia (B12 deficiency) while neurologic damage continues. This is not a drug-drug interaction with MK-677 but a general supplementation caution. Using L-methylfolate at doses of 400 to 800 mcg/day avoids the masking issue because 5-MTHF does not correct macrocytic anemia in the absence of B12.

Folate and Oncology: A Note

High-dose folic acid (above 5,000 mcg/day) has been associated in some observational datasets with accelerated growth of pre-existing colorectal adenomas 12. MK-677 raises IGF-1, and IGF-1 independently promotes cell proliferation. This combination has not been studied directly, and no trial has shown cancer risk from research-dose MK-677. Still, users with a personal or family history of colorectal adenoma or hormone-sensitive malignancy should discuss both agents with a physician before starting.

Known MK-677 Side Effects Relevant to This Stack

MK-677 at 25 mg/day produces a predictable side-effect profile that does not overlap with folate's mechanism but affects clinical monitoring decisions.

Fluid Retention

Fluid retention and transient peripheral edema occur in roughly 26% of users in the 2-year Nass et al. RCT 1. This is GH-mediated, not folate-related, but it affects how a clinician interprets laboratory values (hemodilution may lower serum folate concentration without reflecting a true deficit).

Insulin Resistance

MK-677 raises fasting glucose and insulin in a dose-dependent manner. The Nass trial recorded an increase in fasting blood glucose of approximately 0.3 mmol/L at 25 mg/day versus placebo 1. Insulin resistance is independently associated with elevated homocysteine in some research datasets 13, which reinforces the argument for monitoring homocysteine in users who also have metabolic syndrome or pre-diabetes.

Increased Appetite

Ghrelin-receptor agonism reliably increases appetite, a side effect reported in over 60% of subjects in short-term MK-677 trials 14. Increased caloric intake from diverse whole foods may incidentally improve folate status in users who were previously eating a nutrient-poor diet.

Practical Dosing and Timing Guidance

No dose-separation window is required. Folate does not need to be taken at a different time than MK-677 because their absorption pathways are independent. The following is a reasonable protocol, not a substitute for individualized medical advice.

Suggested Daily Stack Outline

• MK-677: 10 to 25 mg taken orally in the evening (evening dosing aligns the GH pulse with the natural nocturnal surge and may reduce daytime appetite side effects) 15.
• L-Methylfolate: 400 to 800 mcg taken with any meal. Absorption is not food-dependent.
• Methylcobalamin (B12): 500 mcg taken with L-methylfolate, as B12 is the cofactor for the methionine synthase reaction that uses 5-MTHF.
• Monitoring schedule: Baseline labs before starting, repeat IGF-1, homocysteine, fasting glucose, and insulin at 8 weeks.

What to Do If You Are Already Taking Both

If you are already taking folate alongside MK-677 and have not experienced symptoms of folate excess (which are rare at standard doses) or measurable homocysteine elevation, no immediate change is needed. Order the lab panel described above and review results with a clinician to confirm you are within target ranges.

Regulatory and Research Status of MK-677

MK-677 is not approved by the FDA for any human indication. The FDA classifies it as an investigational new drug (IND). It is sold legally in the United States as a "research compound" with labeling prohibiting human consumption, a regulatory loophole that does not protect consumers from legal or health risk 16. The World Anti-Doping Agency (WADA) lists MK-677 under the Prohibited List in category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) 17. Athletes subject to anti-doping rules should not use it.

The absence of FDA approval also means that production quality, purity, and actual dose per capsule are not guaranteed. Third-party certificate-of-analysis (CoA) testing is the minimum due-diligence step for anyone choosing to use this compound.

What Clinicians and Guidelines Say

The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency in adults states: "Growth hormone secretagogues including ghrelin mimetics should not be used outside of controlled clinical trials given the absence of long-term safety data in diverse populations" 18.

Regarding folate and cardiovascular risk management, the American Heart Association's 2006 science advisory notes: "Measurement of plasma homocysteine should be considered in patients with established cardiovascular disease or at high cardiovascular risk, with intervention targeting levels below 10 micromol/L using B-vitamin therapy including folate 400 to 1,000 mcg daily" 11.

Neither guideline was written with MK-677 users in mind, but both inform the monitoring approach described in the decision framework above.

Summary of Interaction Classification

Pharmacokinetic interaction (absorption, distribution, metabolism, excretion): None documented.

Pharmacodynamic interaction (additive, antagonist, or potentiating effects on the same target): None documented at standard research doses of MK-677 (25 mg/day) and standard supplemental folate (400 to 1,000 mcg/day).

Indirect metabolic concern: Plausible for users with MTHFR variants or borderline folate status, given that MK-677-driven IGF-1 elevation may modestly increase homocysteine demand on the methylation cycle.

Clinical recommendation: Test homocysteine before starting MK-677. If homocysteine is above 10 micromol/L or an MTHFR variant is confirmed, add L-methylfolate 400 to 800 mcg/day with methylcobalamin 500 mcg/day and recheck at 8 weeks.